Publications by authors named "Ranjana H Advani"

100Publications

CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.

Arch Pathol Lab Med 2020 Sep 29. Epub 2020 Sep 29.

From the Department of Pathology (Menke, Natkunam, Warnke, Gratzinger), Stanford, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2020-0135-OADOI Listing
September 2020

Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation.

Leuk Lymphoma 2020 Oct 30;61(10):2428-2434. Epub 2020 May 30.

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1768385DOI Listing
October 2020

Updates in Treatment Strategies for Hodgkin Lymphoma.

Authors:
Ranjana H Advani

J Natl Compr Canc Netw 2019 11;17(11.5):1411-1413

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2019.5027DOI Listing
November 2019

Reply to J. Wang et al.

J Clin Oncol 2019 03 12;37(9):755-757. Epub 2019 Feb 12.

David M. Kurtz, MD, PhD; Florian Scherer, MD; Michael C. Jin; Joanne Soo; Alexander F.M. Craig, MPhil; Mohammad S. Esfahani, PhD; Jacob J. Chabon, PhD; Henning Stehr, PhD; Chih Long Liu, PhD; Robert Tibshirani, PhD; Lauren S. Maeda, MD; Neel K. Gupta, MD; Michael S. Khodadoust, MD, PhD; Ranjana H. Advani, MD; and Aaron M. Newman, PhD, Stanford University, Stanford, CA; Ulrich Dührsen, MD; and Andreas Hüttmann, MD, University Hospital Essen, Essen, Germany; Michel Meignan, MD, PhD, Hôpitaux Universitaires Henri Mondor, Creteil, France; Olivier Casasnovas, MD, Centre Hospitalier Universitaire, Dijon, France; Jason R. Westin, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; Mark Roschewski, MD; and Wyndham H. Wilson, MD, PhD, National Institutes of Health, Bethesda, MD; Gianluca Gaidano, MD, PhD; and Davide Rossi, MD, PhD, University of Eastern Piedmont, Novara, Italy, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland; and Maximilian Diehn, MD, PhD; and Ash A. Alizadeh, MD, PhD, Stanford University, Stanford, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01907
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01907DOI Listing
March 2019

Risk-adapted therapy for advanced-stage Hodgkin lymphoma.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):200-206

Division of Oncology, Department of Medicine, Stanford University, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245987PMC
November 2018

Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.

Br J Haematol 2019 01 28;184(1):17-29. Epub 2018 Nov 28.

Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15616DOI Listing
January 2019

New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?

Am Soc Clin Oncol Educ Book 2018 May;38:626-636

From the Department of Medicine, Division of Oncology, Stanford University, Stanford, CA; BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada; Perlmutter Cancer Center at NYU Langone Health, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_200679DOI Listing
May 2018

Novel Approaches in Waldenström Macroglobulinemia.

Hematol Oncol Clin North Am 2018 Oct 19;32(5):875-890. Epub 2018 Jul 19.

Division of Oncology, Department of Medicine, Stanford University, Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08898588183074
Publisher Site
http://dx.doi.org/10.1016/j.hoc.2018.05.014DOI Listing
October 2018

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.

J Clin Oncol 2018 10 4;36(30):3015-3022. Epub 2018 Sep 4.

Andrew M. Evens, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Ranjana H. Advani, Stanford University, Stanford, CA; Irene B. Helenowski, Borko D. Jovanovic, Jane N. Winter, and Leo I. Gordon, Northwestern University Feinberg School of Medicine; Jane N. Winter and Leo I. Gordon, Robert H. Lurie Comprehensive Cancer Center; Sonali M. Smith, University of Chicago, Chicago, IL; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Gregory R. Bociek, University of Nebraska, Omaha, NE; Andreas K. Klein, Tufts Medical Center, Boston, MA; and Paul A. Hamlin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.0139DOI Listing
October 2018

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.

J Clin Oncol 2018 10 20;36(28):2845-2853. Epub 2018 Aug 20.

David M. Kurtz, Florian Scherer, Michael C. Jin, Joanne Soo, Alexander F.M. Craig, Mohammad Shahrokh Esfahani, Jacob J. Chabon, Henning Stehr, Chih Long Liu, Robert Tibshirani, Lauren S. Maeda, Neel K. Gupta, Michael S. Khodadoust, Ranjana H. Advani, Ronald Levy, Aaron M. Newman, Maximilian Diehn, and Ash A. Alizadeh, Stanford University, Stanford, CA; Florian Scherer, University Medical Center Freiburg, Freiburg; Ulrich Dührsen and Andreas Hüttmann, University Hospital Essen, Essen, Germany; Michel Meignan, Hôpitaux Universitaires Henri Mondor, Creteil; René-Olivier Casasnovas, Hôpital Le Bocage, Centre Hospitalier Universitaire, Dijon, France; Jason R. Westin, University of Texas MD Anderson Cancer Center, Houston, TX; Mark Roschewski and Wyndham H. Wilson, National Cancer Institute, National Institutes of Health, Bethesda, MD; Gianluca Gaidano and Davide Rossi, University of Eastern Piedmont, Novara, Italy; and Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.5246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161832PMC
October 2018

Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.

Blood Adv 2018 07;2(13):1547-1550

Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018021071DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039652PMC
July 2018

Advances in the management of primary mediastinal large B-cell lymphoma.

Authors:
Ranjana H Advani

Clin Adv Hematol Oncol 2018 Jan;16(1):33-34

Stanford Cancer Institute, Stanford, California.

View Article

Download full-text PDF

Source
January 2018

Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88 Mutation.

Case Rep Oncol 2017 Sep-Dec;10(3):813-818. Epub 2017 Sep 12.

Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/480292
Publisher Site
http://dx.doi.org/10.1159/000480292DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649220PMC
September 2017

Erratum to: Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.

Curr Treat Options Oncol 2017 10;18(10):60

Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-017-0499-4
Publisher Site
http://dx.doi.org/10.1007/s11864-017-0499-4DOI Listing
October 2017

Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.

Curr Treat Options Oncol 2017 07;18(7):45

Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-017-0483-zDOI Listing
July 2017

Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.

Br J Haematol 2017 07 25;178(1):72-80. Epub 2017 May 25.

Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14638DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487277PMC
July 2017

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

J Natl Compr Canc Netw 2016 09;14(9):1067-79

From Memorial Sloan Kettering Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; The University of Texas MD Anderson Cancer Center; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; UCSF Helen Diller Family Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; Mayo Clinic Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; Duke Cancer Institute; Consultant; Dana-Farber/Brigham and Women's Cancer Center; Fred & Pamela Buffett Cancer Center; City of Hope Comprehensive Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Colorado Cancer Center; Vanderbilt-Ingram Cancer Center; UC San Diego Moores Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Alabama at Birmingham Comprehensive Cancer Center; Moffitt Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; St. Jude Children's Research Hospital/University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0117DOI Listing
September 2016

Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.

Br J Haematol 2018 01 18;180(1):164-166. Epub 2016 Aug 18.

Department of Medicine, Division of Oncology, Stanford University, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14302DOI Listing
January 2018

Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.

Clin Adv Hematol Oncol 2016 Jul;14(7):543-54

Stanford University Medical Center, Stanford, California.

View Article

Download full-text PDF

Source
July 2016

Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT.

Am Soc Clin Oncol Educ Book 2016 ;35:e376-85

From the Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_159036DOI Listing
January 2017

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Arch Pathol Lab Med 2016 Nov 15;140(11):1228-1230. Epub 2016 Apr 15.

From the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri (Drs Duncavage and Rosenbaum); the Departments of Medicine, Oncology Division (Dr Advani), and Pathology (Dr Ohgami), Stanford University Medical Center, Stanford, California; the Pathology & Laboratory Medicine Service, James A. Haley Veterans Affairs Medical Center, Tampa, Florida (Drs Agosti, Foulis, and Kang); Blood and Marrow Transplantation, the Moffitt Cancer Center, Tampa, Florida (Ms Gibson); the Department of Hematopathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston (Drs Khoury, Medeiros, and Patel); the Department of Pathology, Clarient Pathology Services, Aliso Viejo, California (Dr O'Malley); and the Department of Hematopathology, University of New Mexico Health Sciences Center, Albuquerque (Dr Wilson).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2016-0045-CPDOI Listing
November 2016

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.

Arch Pathol Lab Med 2016 11 15;140(11):1225-1227. Epub 2016 Apr 15.

From the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri (Drs Duncavage and Rosenbaum); the Departments of Medicine, Oncology Division (Dr Advani), and Pathology (Dr Ohgami), Stanford University Medical Center, Stanford, California; the Pathology & Laboratory Medicine Service, James A. Haley Veterans Affairs Medical Center, Tampa, Florida (Drs Agosti, Foulis, and Kang); the Moffitt Cancer Center, Tampa, Florida (Ms Gibson); the Department of Hematopathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston (Drs Khoury, Medeiros, and Patel); the Department of Pathology, Clarient Pathology Services, Aliso Viejo, California (Dr O'Malley); and the Department of Hematopathology, University of New Mexico Health Sciences Center, Albuquerque (Dr Wilson).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2015-0418-CPDOI Listing
November 2016

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

J Clin Oncol 2016 08 11;34(23):2690-7. Epub 2016 Apr 11.

Margaretha G.M. Roemer, Robert A. Redd, Heather Homer, Courtney F. Connelly, Gordon J. Freeman, Philippe Armand, Bjoern Chapuy, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Azra H. Ligon, Heather H. Sun, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer and Daphne de Jong, VU University Medical Center, Amsterdam, the Netherlands; and Ranjana H. Advani, Yasodha Natkunam, Sarah E. Daadi, and Richard T. Hoppe, Stanford University Medical Center, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.4482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019753PMC
August 2016

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

J Clin Oncol 2015 Nov 20;33(32):3750-8. Epub 2015 Jul 20.

Youn H. Kim, Mahkam Tavallaee, Uma Sundram, Shufeng Li, Sima Rozati, Seema Nagpal, Michael Krathen, Sunil Reddy, Richard T. Hoppe, Annie Nguyen-Lin, Wen-Kai Weng, Randall Armstrong, and Ranjana H. Advani, Stanford University, Stanford, CA; Katrin A. Salva and Gary S. Wood, University of Wisconsin and William S. Middleton Memorial Veterans Hospital, Madison, WI; and Melissa Pulitzer and Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.3969DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089160PMC
November 2015

Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.

Curr Treat Options Oncol 2015 Sep;16(9):45

Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-015-0360-6DOI Listing
September 2015

A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.

Leuk Lymphoma 2016 28;57(3):604-8. Epub 2015 Aug 28.

a Department of Radiation Oncology , Stanford University School of Medicine , Stanford , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1067700DOI Listing
December 2016

XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma.

Hematol Oncol 2015 Jun;33 Suppl 1:90-5

Stanford Cancer Institute, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2226DOI Listing
June 2015

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

J Clin Oncol 2015 Jun 20;33(17):1936-42. Epub 2015 Apr 20.

Ranjana H. Advani, Richard T. Hoppe, and Sandra J. Horning, Stanford University, Stanford; Joseph M. Tuscano, University of California, Davis Cancer Center, Sacramento, CA; Fangxin Hong, Dana-Farber Cancer Institute, Boston, MA; Richard I. Fisher and Jonathan W. Friedberg, University of Rochester, Rochester, NY; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; K. Sue Robinson, Queen Elizabeth II Health Science Center, Halifax, Nova Scotia; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia; Douglas A. Stewart, Tim Baker Cancer Institute, Calgary, Alberta, Canada; Henry Wagner Jr, Penn State Cancer Institute, Hershey, PA; Patrick J. Stiff, Loyola University Medical Center, Maywood; Leo I. Gordon, Northwestern University, Chicago, IL; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Brad S. Kahl, University of Wisconsin, Madison, WI; Kristie A. Blum, Ohio State University, Columbus, OH; and Thomas M. Habermann, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/15/JCO.2014.57
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.8138
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.8138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451176PMC
June 2015

Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.

Int J Radiat Oncol Biol Phys 2015 May;92(1):99-106

Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.01.039DOI Listing
May 2015

Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.

Int J Radiat Oncol Biol Phys 2015 May;92(1):67-75

Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.02.001DOI Listing
May 2015

Ibrutinib in previously treated Waldenström's macroglobulinemia.

N Engl J Med 2015 Apr;372(15):1430-40

From the Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute (S.P.T., C.K.T., K.M., D.W., G.Y., Y.C., L.X., C.J.P., S.K., I.G., J.J.C., J.P.L., Z.R.H.), Harvard Medical School (S.P.T., G.Y., Y.C., S.R., J.C.A., N.L.H., I.G., J.J.C., J.P.L.), Department of Pathology, Brigham and Women's Hospital (S.R., J.C.A.), Department of Pathology, Massachusetts General Hospital (N.L.H.), and Department of Pathology, Boston University Medical Center (Z.R.H.) - all in Boston; Memorial Sloan Kettering Cancer Center, New York (R.G., K.V.A., M.L.P.); and Stanford University Medical Center, Stanford (G.V., J.L.Z., R.H.A.), and Pharmacyclics, Sunnyvale (Z.S., J.L., M.C., F.C., T.G.) - both in California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1501548DOI Listing
April 2015

Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).

J Clin Oncol 2015 Mar 20;33(7):740-8. Epub 2015 Jan 20.

Lynne I. Wagner and David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL; Fengmin Zhao, Fangxin Hong, Dana-Farber Cancer Institute, Boston, MA; Michael E. Williams, University of Virginia, Charlottesville, VA; John C. Krauss, University of Michigan, Ann Arbor, MI; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Ronald S. Go, Gunderson Health System, La Crosse; Brad S. Kahl, University of Wisconsin, Madison, WI; Thomas M. Habermann, Mayo Clinic, Rochester; Joseph W. Leach, Metro Minnesota Community Clinical Oncology Program, Minneapolis, MN; Brian O'Connor, Frederick Memorial Health System, Frederick, MD; Stephen J. Schuster, University of Pennsylvania, Philadelphia, PA; and Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/7/740.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.6801
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.6801DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334777PMC
March 2015

Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution.

Biol Blood Marrow Transplant 2015 Feb 29;21(2):326-34. Epub 2014 Oct 29.

Department of Pediatrics, Stanford University School of Medicine, Stanford, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.10.020DOI Listing
February 2015

Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.

Ther Adv Hematol 2014 Aug;5(4):121-33

Stanford University Medical Center, 875 Blake Wilbur Dr, Suite CC-2338, Stanford, CA 94305-5821, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620714539906DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212313PMC
August 2014

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.

J Clin Oncol 2014 Oct 18;32(28):3137-43. Epub 2014 Aug 18.

Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner, Takeda Pharmaceuticals International, Cambridge, MA; Dana A. Kennedy, Seattle Genetics, Bothell; Andrei R. Shustov, University of Washington Medical Center, Seattle, WA; Andrew Davies, University of Southampton School of Medicine, Southampton; Tim Illidge, Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.2456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171358PMC
October 2014

Bulky mediastinal classical Hodgkin lymphoma in young women.

Oncology (Williston Park) 2014 Mar;28(3):253-6, 258-60, C3

View Article

Download full-text PDF

Source
March 2014

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

Blood 2014 May 20;123(20):3095-100. Epub 2014 Mar 20.

Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-12-542142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425442PMC
May 2014

Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.

J Clin Oncol 2014 Mar 10;32(9):912-8. Epub 2014 Feb 10.

Ranjana H. Advani, Sandra J. Horning, Richard T. Hoppe, Sarah Daadi, John Allen, and Yasodha Natkunam, Stanford University Medical Center, Stanford, CA; and Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.2069DOI Listing
March 2014

Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma.

Am J Clin Oncol 2016 Apr;39(2):114-9

Departments of *Radiation Oncology †Medicine ‡Radiology, Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079764PMC
April 2016

How I treat nodular lymphocyte predominant Hodgkin lymphoma.

Blood 2013 Dec 8;122(26):4182-8. Epub 2013 Nov 8.

Medical Oncology, and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-07-453241DOI Listing
December 2013

Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.

Br J Haematol 2013 Nov 24;163(4):436-43. Epub 2013 Sep 24.

Stanford University Medical Center, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12573DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444436PMC
November 2013